Clinical significance of quantitative assessment of right ventricular glucose metabolism in patients with heart failure with reduced ejection fraction.

Szu-Ying Tsai, Yen-Wen Wu, Shan-Ying Wang, Yu-Chien Shiau, Kuan-Ming Chiu, Hao-Yuan Tsai, Chien-Lin Lee, Jung-Cheng Hsu, Chung-Ming Tu, Heng-Hsu Lin, Shan-Hui Huang
Author Information
  1. Szu-Ying Tsai: Department of Nuclear Medicine, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist, New Taipei City, 220, Taiwan.
  2. Yen-Wen Wu: Department of Nuclear Medicine, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist, New Taipei City, 220, Taiwan. wuyw0502@gmail.com. ORCID
  3. Shan-Ying Wang: Department of Nuclear Medicine, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist, New Taipei City, 220, Taiwan.
  4. Yu-Chien Shiau: Department of Nuclear Medicine, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist, New Taipei City, 220, Taiwan.
  5. Kuan-Ming Chiu: Division of Cardiovascular Surgery, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  6. Hao-Yuan Tsai: Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  7. Chien-Lin Lee: Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  8. Jung-Cheng Hsu: Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  9. Chung-Ming Tu: Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  10. Heng-Hsu Lin: Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  11. Shan-Hui Huang: Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.

Abstract

PURPOSE: Dynamic F-fluorodeoxyglucose (FDG) PET can be used to quantitatively assess the rate of myocardial glucose uptake (MRGlu). The aim of this study was to evaluate the clinical significance and prognostic value of right ventricular (RV) MRGlu in patients with coronary artery disease and heart failure with reduced ejection fraction.
METHODS: Patients with left ventricular ejection fraction (LVEF) ≤ 40% were consecutively enrolled for FDG PET between November 2012 and May 2017. Global LV and RV MRGlu (μmol/min/100 g) were analyzed. Outcome events were independently assessed using electronic medical records to determine hospitalization for revascularization, new-onset ischemic events, heart failure, cardiovascular, and all-cause death. Differences between LV and RV MRGlu and associations with clinical characteristics and echocardiographic data were evaluated. Associations among FDG PET findings and outcomes were analyzed using Kaplan-Meier survival analysis.
RESULTS: Seventy-five patients (mean age 62.2 ± 12.7 years, male 85.3%, LVEF 19.3 ± 8.6%) were included for analysis. The mean glucose utilization ratio of RV-to-LV (RV/LV MRGlu) was 89.5 ± 264.9% (r = 0.77, p < 0.001). Positive correlations between RV MRGlu and maximal tricuspid regurgitation peak gradient (r = 0.28, p = 0.033) and peak tricuspid regurgitation jet velocity (r = 0.29, p = 0.021) were noted. LVEF was positively correlated with LV MRGlu (r = 0.27, p = 0.018), but negatively correlated with end-diastolic volume (r = - 0.37, p = 0.001), end-systolic volume (r = - 0.54, p < 0.001), and RV/LV MRGlu (r = - 0.40, p < 0.001). However, RV MRGlu was not well correlated with LVEF. Forty-three patients received revascularization procedures after FDG PET, and 13 patients died in a mean follow-up period of 496 ± 453 days (1-1788 days), including nine cardiovascular deaths. Higher RV and LV MRGlu values, LVEF ≤ 16% and LV end-diastolic volume ≥ 209 ml of gated-PET were associated with poor overall survival and cardiac outcomes.
CONCLUSIONS: In patients with coronary artery disease and ischemic cardiomyopathy, RV glucose utilization was positively correlated with RV pressure overload, but not LVEF. Global LV and RV MRGlu, LVEF, and LV end-diastolic volume showed significant prognostic value.

Keywords

References

  1. Card Fail Rev. 2017 Apr;3(1):7-11 [PMID: 28785469]
  2. Circ Heart Fail. 2013 Jul;6(4):748-55 [PMID: 23709658]
  3. Clin Med Insights Cardiol. 2015 Feb 25;9(Suppl 1):11-31 [PMID: 25780344]
  4. J Heart Lung Transplant. 2017 Sep;36(9):957-967 [PMID: 28302503]
  5. Cardiovasc Res. 2017 Oct 1;113(12):1423-1432 [PMID: 28957530]
  6. Circ Res. 2018 Jun 22;123(1):107-128 [PMID: 29929976]
  7. J Nucl Cardiol. 2010 Jan-Feb;17(1):52-60 [PMID: 19826892]
  8. Circ Cardiovasc Imaging. 2011 Nov;4(6):641-7 [PMID: 21926260]
  9. J Nucl Med. 2005 Jan;46(1):25-31 [PMID: 15632029]
  10. Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1424-1431 [PMID: 26060207]
  11. Eur Heart J. 2016 Jul 14;37(27):2129-2200 [PMID: 27206819]
  12. BMC Cardiovasc Disord. 2016 Nov 21;16(1):232 [PMID: 27871223]
  13. Heart. 2002 Oct;88(4):323-4 [PMID: 12231578]
  14. J Nucl Med. 2007 Jul;48(7):1096-103 [PMID: 17607039]
  15. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8 [PMID: 24355634]
  16. Diabetol Metab Syndr. 2018 Mar 15;10:19 [PMID: 29568331]
  17. Circulation. 2010 Jan 19;121(2):259-66 [PMID: 20048214]
  18. J Nucl Med Technol. 2010 Dec;38(4):175-80 [PMID: 21078778]
  19. J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486 [PMID: 29141781]
  20. J Nucl Cardiol. 2016 Oct;23(5):1187-1226 [PMID: 27392702]
  21. Int J Cardiol Heart Vasc. 2016 Jul 04;12:45-51 [PMID: 28616542]
  22. J Am Coll Cardiol. 2018 Mar 20;71(11):1273-1283 [PMID: 29544612]
  23. BMC Cardiovasc Disord. 2018 Oct 29;18(1):203 [PMID: 30373519]
  24. J Nucl Med. 2017 Jul;58(7):1019-1024 [PMID: 28522743]
  25. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S69-77 [PMID: 21484383]
  26. Circulation. 2006 Oct 24;114(17):1883-91 [PMID: 17060398]
  27. Chest. 2004 Oct;126(4):1313-7 [PMID: 15486398]
  28. J Nucl Med. 1999 Jun;40(6):889-94 [PMID: 10452302]
  29. Int J Cardiol. 2016 Nov 15;223:163-167 [PMID: 27541646]
  30. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8 [PMID: 20620859]
  31. J Nucl Cardiol. 2018 Aug 14;:null [PMID: 30109593]
  32. Clin Nucl Med. 2017 Sep;42(9):e392-e399 [PMID: 28590298]
  33. Eur Heart J Cardiovasc Imaging. 2016 Oct;17(10):1161-8 [PMID: 26588985]
  34. J Am Coll Cardiol. 2013 Oct 29;62(18):1724 [PMID: 24008136]
  35. Eur Respir J. 2019 Jan 24;53(1):null [PMID: 30552088]
  36. Acta Cardiol Sin. 2016 Jul;32(4):400-11 [PMID: 27471353]
  37. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239 [PMID: 23747642]
  38. Circulation. 1996 May 1;93(9):1658-66 [PMID: 8653871]
  39. Chest. 2015 Jan;147(1):198-208 [PMID: 25211049]
  40. Pulm Circ. 2012 Jul;2(3):365-72 [PMID: 23130105]
  41. Curr Cardiol Rev. 2013 May;9(2):112-22 [PMID: 23597295]
  42. Eur J Heart Fail. 2015 Nov;17(11):1161-71 [PMID: 26467180]
  43. Curr Heart Fail Rep. 2018 Apr;15(2):94-105 [PMID: 29468529]
  44. Pulm Circ. 2018 Jan-Mar;8(1):2045893217743122 [PMID: 29099675]
  45. Circ Cardiovasc Imaging. 2017 Aug;10(8): [PMID: 28794138]
  46. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):532-41 [PMID: 23287994]
  47. J Am Soc Echocardiogr. 2013 Jan;26(1):1-14 [PMID: 23140849]
  48. J Nucl Cardiol. 2017 Dec;24(6):1979-1989 [PMID: 27688036]
  49. Int J Cardiol. 2005 Sep 15;104(1):39-45 [PMID: 16137508]

MeSH Term

Aged
Cohort Studies
Female
Fluorodeoxyglucose F18
Follow-Up Studies
Glucose
Heart Failure
Heart Ventricles
Humans
Male
Middle Aged
Positron-Emission Tomography
Retrospective Studies
Stroke Volume

Chemicals

Fluorodeoxyglucose F18
Glucose

Word Cloud

Created with Highcharts 10.0.0MRGluRVLVpatientsLVEFglucoseFDGPETfailurer = 0001p = 0correlatedventricularheartejectionfractionmeanp < 0end-diastolicvolumer = - 0myocardialuptakeclinicalsignificanceprognosticvaluerightcoronaryarterydiseasereducedGlobalanalyzedeventsusingrevascularizationischemiccardiovascularoutcomessurvivalanalysisutilizationRV/LVtricuspidregurgitationpeakpositivelyPURPOSE:DynamicF-fluorodeoxyglucosecanusedquantitativelyassessrateaimstudyevaluateMETHODS:Patientsleft ≤ 40%consecutivelyenrolledNovember2012May2017μmol/min/100 gOutcomeindependentlyassessedelectronicmedicalrecordsdeterminehospitalizationnew-onsetall-causedeathDifferencesassociationscharacteristicsechocardiographicdataevaluatedAssociationsamongfindingsKaplan-MeierRESULTS:Seventy-fiveage622 ± 127 yearsmale853%193 ± 86%includedratioRV-to-LV895 ± 2649%77Positivecorrelationsmaximalgradient28033jetvelocity29021noted27018negatively37end-systolic5440HoweverwellForty-threereceivedprocedures13diedfollow-upperiod496 ± 453 days1-1788 daysincludingninedeathsHighervaluesLVEF ≤ 16%volume ≥ 209 mlgated-PETassociatedpooroverallcardiacCONCLUSIONS:cardiomyopathypressureoverloadshowedsignificantClinicalquantitativeassessmentmetabolism18F-fluorodeoxyglucoseHeartPositronemissiontomographyRateRightventricle

Similar Articles

Cited By